Regen BioPharma Inc (RGBP)

[Namaste Charting]

Fact of the matter is...the 2 license agreements that $rgbp has just signed with $onph that folks are trying to dust under the rug screaming scam would of in no way no how entered in collaboration with the likes of Ely lilly...$lly $187 dollar monster of big pharma with 22 billion revenues last year

those screaming foul play are those that want your shares, i could care less if this collaboration is still in place, what matters is what is now in place with mrna & $onph...plus i think there are way more pieces of the puzzle we still have not put together

we are are ground zero here & i will do all in my power to take advantage of the few extra shares added to the o/s to give us this opportunity @ just ridiculous bottom prices...under 100 million market cap, not gonna fly here much longer imo

https://www.contractpharma.com/contents/view_breaking-news/2016-06-30/lilly-regen-biopharma-in-drug-discovery-pact/

Lilly, Regen BioPharma in Drug Discovery Pact

Regen will examine 21,000 Lilly compounds in its NR2F6 high-throughput screening program
Related CONTENT

PAREXEL Appoints SVP, CFO
Boehringer, Inovalon Enter Cloud Platform Pact
Lilly to Acquire CoLucid Pharma
12 Lilly
Intellectual Property for the Pharmaceutical Industry

06.30.16
Regen BioPharma has entered into a definitive agreement with Eli Lilly and Co. to receive compounds from Lilly for drug discovery purposes and allows Regen to share structural information on compounds of mutual interest.

Regen will examine 21,000 Lilly compounds in its NR2F6 high-throughput screening program to identify activators and inhibitors of this protein. NR2F6 is a molecular switch known as an "orphan nuclear receptor," which controls genes associated with the immune response as well as genes associated with the ability of cancer stem cells to propagate.

Lilly has an option to negotiate a compound purchase agreement, a license agreement, or a research collaboration agreement for further research and development of material of mutual interest.

"Lilly's Open Innovation Drug Discovery Program is visionary," said Harry Lander, Ph.D., MBA, president and chief scientific officer of Regen BioPharma, Inc. "They understand the value of partnering in a confidential manner with smaller entities that may have intellectual property that aligns with their product goals.”